Biomarin Pharmaceutical Inc - Asset Resilience Ratio
Biomarin Pharmaceutical Inc (BMRN) has an Asset Resilience Ratio of 0.00% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See BMRN working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how Biomarin Pharmaceutical Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Biomarin Pharmaceutical Inc assets under control.
Liquid Assets Composition Over Time
This chart breaks down Biomarin Pharmaceutical Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore BMRN long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Biomarin Pharmaceutical Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Biomarin Pharmaceutical Inc Industry Peers by Asset Resilience Ratio
Compare Biomarin Pharmaceutical Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Vaxcyte Inc
NASDAQ:PCVX |
Biotechnology | 41.54% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 38.51% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
Annual Asset Resilience Ratio for Biomarin Pharmaceutical Inc (1999–2025)
The table below shows the annual Asset Resilience Ratio data for Biomarin Pharmaceutical Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.28% | $248.93 Million | $7.59 Billion | +0.49pp |
| 2024-12-31 | 2.79% | $194.86 Million | $6.99 Billion | -1.87pp |
| 2023-12-31 | 4.66% | $318.68 Million | $6.84 Billion | -4.24pp |
| 2022-12-31 | 8.89% | $567.01 Million | $6.38 Billion | +1.79pp |
| 2021-12-31 | 7.11% | $426.60 Million | $6.00 Billion | -0.01pp |
| 2020-12-31 | 7.12% | $416.23 Million | $5.85 Billion | +0.37pp |
| 2019-12-31 | 6.75% | $316.36 Million | $4.69 Billion | -6.59pp |
| 2018-12-31 | 13.33% | $590.33 Million | $4.43 Billion | -3.89pp |
| 2017-12-31 | 17.22% | $797.94 Million | $4.63 Billion | +7.74pp |
| 2016-12-31 | 9.48% | $381.35 Million | $4.02 Billion | +4.23pp |
| 2015-12-31 | 5.24% | $195.58 Million | $3.73 Billion | +2.45pp |
| 2014-12-31 | 2.80% | $69.71 Million | $2.49 Billion | -6.82pp |
| 2013-12-31 | 9.62% | $215.94 Million | $2.24 Billion | -7.61pp |
| 2012-12-31 | 17.23% | $270.21 Million | $1.57 Billion | +5.83pp |
| 2011-12-31 | 11.40% | $148.82 Million | $1.31 Billion | -3.34pp |
| 2010-12-31 | 14.73% | $186.03 Million | $1.26 Billion | +0.18pp |
| 2009-12-31 | 14.56% | $133.51 Million | $917.16 Million | -22.60pp |
| 2008-12-31 | 37.16% | $336.89 Million | $906.70 Million | -6.66pp |
| 2007-12-31 | 43.82% | $357.25 Million | $815.28 Million | +0.73pp |
| 2006-12-31 | 43.09% | $199.69 Million | $463.44 Million | +38.12pp |
| 2005-12-31 | 4.97% | $9.70 Million | $195.30 Million | -10.37pp |
| 2004-12-31 | 15.34% | $35.73 Million | $232.97 Million | -17.80pp |
| 2003-12-31 | 33.14% | $84.95 Million | $256.34 Million | -3.33pp |
| 2002-12-31 | 36.47% | $40.34 Million | $110.62 Million | -32.54pp |
| 2001-12-31 | 69.01% | $118.57 Million | $171.81 Million | +38.24pp |
| 2000-12-31 | 30.77% | $23.67 Million | $76.93 Million | -7.45pp |
| 1999-12-31 | 38.22% | $39.57 Million | $103.55 Million | -- |
About Biomarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV t… Read more